Star Combo Pharma Ltd (S66) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Star Combo Pharma Ltd A$0.42, price A$0.14, upside +200.0%, quality 77 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Star Combo Pharma Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range A$0.0865 – A$0.3604 · fair‑value band A$0.2940 – A$0.5940 · the A$0.1400 price screens below the A$0.4200 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Star Combo Pharma in your weekly email
Every Wednesday you see whether Star Combo Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products.
Show more
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its products under the Costar, Living Healthy, Amax, and J&K brands. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Stock analysis
Star Combo Pharma Ltd (S66) currently trades at A$0.1400, while our model-based Fair Value estimate is A$0.4200, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of A$0.9400 per share, and 21 of the 21 models we run sit above the A$0.1400 price.
Bear case: the Asset-Based group reads lowest at A$0.1900, and 0 of the 21 models stay below the price. Evidence for this calculation is low.
Scenario range: A$0.2940 (bear) to A$0.5940 (bull), the price of A$0.1400 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Star Combo Pharma Ltd reported revenue of A$27.8M in FY2025 versus A$26.7M in FY2021, a compound +1.0%/yr. Reported net income was A$5.2M in FY2025.
Key figures
Market cap A$18.9M (≈ $13.3M) · P/E ratio 3.5 · P/S ratio 0.66 · EPS (TTM) A$0.0400 · Dividend yield 2.9% · Net margin 18.9% · Return on equity 14.9% · Return on assets (EBIT) −0.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −14% fair-value upside, at 200%, S66 screens cheaper than that median.
Fair Value models
Bear A$0.2940Fair Value A$0.4200Bull A$0.5940
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (A$0.0360 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.5%
Start year 2020 (pandemic). Over 10 years: +15.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 251 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside+200% · Top 25%
Profitability
Return on equity (TTM)15% · Above median
Return on assets7% · Above median
Net margin (TTM)22% · Top 25%
Operating margin (TTM)1% · Below median
Growth and dividend
Revenue growth−24% · Bottom 25%
Dividend yield (TTM)2.9% · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Star Combo Pharma Ltd (S66) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$0.4200 versus a price of A$0.1400, about +200% upside (undervalued).
What is the fair value of S66?
Our model-based fair value for Star Combo Pharma Ltd is A$0.4200 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$0.1400.
What is the quality score of S66?
Star Combo Pharma Ltd has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Star Combo Pharma Ltd (S66)?
Our model-based price target is the fair value of A$0.4200 (as of Sep 23, 2026) from 21 valuation models. Cautious scenario A$0.2940, optimistic scenario A$0.5940. It is a calculation from audited fundamentals, not an analyst target.
What is the Star Combo Pharma Ltd stock forecast for 2026?
Our models put fair value at A$0.4200, about +200% upside versus a price of A$0.1400 (undervalued). Cautious scenario A$0.2940, optimistic scenario A$0.5940. The calculation is refreshed regularly with new filings.
What is the revenue of Star Combo Pharma Ltd (S66)?
Star Combo Pharma Ltd reported trailing-twelve-month revenue of about A$24.0M (latest available figure, as of Sep 23, 2026).
Does Star Combo Pharma Ltd pay a dividend?
Star Combo Pharma Ltd currently shows a dividend yield of about 2.86% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Star Combo Pharma Ltd (S66)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Star Combo Pharma Ltd it is A$0.4200 per share (as of Sep 23, 2026), against a price of A$0.1400. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Star Combo Pharma Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, S66 trades below its calculated fair value: price A$0.1400, fair value A$0.4200, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of S66?
No. The price is what the market pays today (A$0.1400); the fair value is what the company's own numbers justify (A$0.4200). For Star Combo Pharma Ltd the two are A$0.2800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Star Combo Pharma Ltd worth?
The market values Star Combo Pharma Ltd at about A$18.9M (market capitalisation, as of Sep 23, 2026). Per share that is A$0.1400; our models calculate a fair value of A$0.4200 per share.
What do the bullish and bearish scenarios say about S66?
Our models span a range for Star Combo Pharma Ltd: cautious scenario A$0.2940, base A$0.4200, optimistic A$0.5940 per share (as of Sep 23, 2026, price A$0.1400). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of S66?
Star Combo Pharma Ltd trades at a price-to-earnings ratio of 3.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$0.4200 is built from several models across several years. Other multiples: P/B 0.4, P/S 0.6, EV/EBITDA 1.4.
How solid is the balance sheet of Star Combo Pharma Ltd (S66)?
Balance-sheet figures for Star Combo Pharma Ltd (as of Sep 23, 2026): return on equity 14.9%. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is S66 from its 52-week high?
Star Combo Pharma Ltd trades at A$0.1400, about 48% below its 52-week high of A$0.2700 and 27% above the low of A$0.1100 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.4200 is for.
Which stocks are comparable to Star Combo Pharma Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Star Combo Pharma Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$0.1400, calculated fair value A$0.4200 (+200%), Quality Score 77/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of S66 calculated?
We run Star Combo Pharma Ltd through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.4200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Star Combo Pharma Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Star Combo Pharma Ltd (S66)?
The closing price on Sep 24, 2026 was A$0.1400. Our model-based fair value is A$0.4200, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Star Combo Pharma Ltd right now?
The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (A$0.2940). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (A$0.2940 to A$0.5940) leaves room in how you read the outcome.
Key figures of Star Combo Pharma Ltd
How large is the market capitalisation of Star Combo Pharma Ltd (S66)?
The market capitalisation of Star Combo Pharma Ltd is A$18.9M (≈ $13.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Star Combo Pharma Ltd (S66)?
The price-to-sales ratio of Star Combo Pharma Ltd is 0.66 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Star Combo Pharma Ltd (S66)?
Earnings per share at Star Combo Pharma Ltd are A$0.0400 (price ÷ EPS = P/E 3.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Star Combo Pharma Ltd (S66)?
The dividend yield of Star Combo Pharma Ltd is 2.9% (payout 10.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Star Combo Pharma Ltd (S66)?
The net margin of Star Combo Pharma Ltd is 18.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Star Combo Pharma Ltd (S66)?
The return on equity (ROE) of Star Combo Pharma Ltd is 14.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Star Combo Pharma Ltd (S66)?
On an EBIT basis the return on assets of Star Combo Pharma Ltd is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Star Combo Pharma Ltd (S66)?
The operating margin of Star Combo Pharma Ltd is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Star Combo Pharma Ltd (S66)?
Revenue at Star Combo Pharma Ltd is growing −24.2% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Star Combo Pharma Ltd (S66)?
Earnings per share at Star Combo Pharma Ltd are growing +50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Star Combo Pharma Ltd (S66) generate?
The free cash flow of Star Combo Pharma Ltd is A$11.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Star Combo Pharma Ltd (S66) carry?
The net debt of Star Combo Pharma Ltd is A$341K (fiscal year 2025, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Star Combo Pharma Ltd in the live analysis
One click puts Star Combo Pharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
